Research programme: CNS disorder gene therapies - EditForce
Alternative Names: Research programme: gene therapies for CNS disorders - EditForceLatest Information Update: 12 Jul 2022
At a glance
- Originator EditForce; Mitsubishi Tanabe Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders